The matrix metalloproteinases and their synthetic inhibitors in tumor progression;Les métalloprotéases matricielles et leurs inhibiteurs synthétiques dans la progression tumorale

Medecine/Sciences

Volumn 18, Issue 5, 2002, Pages 565-575

  Chantrain, Christophe ^a   DeClerck, Yves A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; BATIMASTAT; CARBOPLATIN; CGS 27023A; CISPLATIN; FLUOROURACIL; GELATINASE; GEMCITABINE; INTERSTITIAL COLLAGENASE; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MEMBRANE ENZYME; MITOXANTRONE; PACLITAXEL; PREDNISONE; PRINOMASTAT; REBIMASTAT; STROMELYSIN; TANOMASTAT;

ANEMIA; ANGIOGENESIS; CANCER; CANCER INVASION; CANCER THERAPY; CELL ADHESION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SPECIFICITY; ENZYME ANALYSIS; ENZYME STRUCTURE; EXTRACELLULAR MATRIX; HUMAN; LIVER TOXICITY; METASTASIS; MUSCULOSKELETAL DISEASE; NONHUMAN; PROTEIN DEGRADATION; REGULATORY MECHANISM; REVIEW; SKIN TOXICITY; THROMBOCYTOPENIA; TUMOR GROWTH;

ANIMALIA;

EID: 18244430501     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2002185565     Document Type: Review

References (48)

1. Matrix metalloproteinases: Biologic activity and clinical implications
2. Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin
3. Matrix metalloproteinases in tumor invasion and metastasis
4. Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer
5. Role of tissue inhibitor of metalloproteinases-2 (TIMP-2) in regulation of pro-gelatinase A activation catalyzed by membranetype matrix metalloproteinase-1 (MT1-MRP) in human cancer cells
6. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages
7. Identification and structural and functional characterization of human enamelysin (MMP-20)
8. Insights into MMP-TIMP interactions
9. Proteclytic remodeling of extracellular matrix
10. Activation mechanisms of matrix metalloproteinases
11. Matrix metalloproteinase stromelysis-1 triggers a cascade of molecular alterations that leads to stable epithelial-tomesenchymal conversion and a premalignant phenotype in mammary epithelial cells
12. The metalloproteinase matrilysin is a target of b-catenin transactivation in intestinal tumors
13. Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis
14. Matrix metalloproteinases as stromal effectors of human carcinoma progression: Therapeutic implications
15. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases
16. Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1
17. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases
18. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact
19. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP-1, inhibit shedding of tumor necrosis factor-α receptors in a human colon adenocarcinoma (Colo 205) cell line
20. KIP1
21. Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival
22. High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase
23. Stromelysin-3 suppresses tumor cell apoptosis in a murine model
24. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
25. Matrix metalloproteinases generate angiostatin: Effects on neovascularization
26. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collogenase (MMP-9)
27. Regulation of angiostatin production by matrix metolloproteinase-2 in a model of concomitant resistance
28. The generation of endostatin is mediated by elastase
29. Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade
30. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth
31. Development of matrix metalloproteinase inhibitors in cancer therapy
32. Clinical studies with matrix metalloproteinase inhibitors
33. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer
34. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
35. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
36. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor
37. Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94)
38. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts
39. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites
40. Phase I trial of Marimastat, a navel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer
41. A phase I study of AG3340, a matrix metalloprotease inhibitor, in patients having advanced cancer
42. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566
43. Promising new developments in cancer chemotherapy
44. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MM1270 (CGS27023a), in patients with advanced solid cancer
45. Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions
46. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
47. In vivo molecular target assessment of matrix metalloproteinase inhibition
48. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy